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Introduction: The rare and orphan diseases (ERH) constitute a current challenge due to the little attention
given to them. Objectives: Describe the socioeconomic characteristics of rare and orphan diseases (ERH)
in Peru, 2019. Methods: Descriptive observational design. The information was obtained from FISSAL
administrative records and an intentional sample of 20 patients was taken to carry out the questionnaire
on ERH. For economic records, a review of the public budget of the MEF was made. The data analysis was
descriptive and inferential. Results: There were 454 patients with a total of 49 ERH, of these, the most
representative age groups were schoolchildren and young adults (18% each) and the most frequent
diagnosis was Tetralogy of Fallot (22%). The questionnaire on ERH reports a median of 7 months in the
delay of diagnosis and between 3 and 5 doctors were visited. Likewise, 30% considered that it generated
a high to very high expense. It was calculated that the ERH budget constitutes 2.25% of the total budget
for high-cost diseases, likewise, the ERH budget was different between 2014 and 2019. Conclusions: The
population with ERH in Peru is not large; however, it requires greater attention to access to health services,
as well as a greater budget allocation.
Key words: Rare diseases; Cost of illness; Economics; Health economics; Peru (source: MeSH NLM).

RESUMEN
Introducción: Las enfermedades raras y huérfanas (ERH) constituyen un desafío actual debido a la poca
atención que se les da. Ojetivos: Describir las características socioeconómicas de las enfermedades raras
y huérfanas (ERH) en el Perú, 2019. Métodos: Diseño observacional descriptivo. Se obtuvo la información
a partir de registros administrativos del FISSAL y se tomó una muestra intencional de 20 pacientes para
realizar el cuestionario sobre ERH. Para los registros económicos se hizo una revisión del presupuesto
público del MEF. El análisis de datos fue descriptivo e inferencial. Resultados: Hubo 454 pacientes con un
total de 49 ERH, de estos, los grupos de edades más representativos fueron los escolares y adultos jóvenes
(18% cada uno) y el diagnóstico más frecuente fue la Tetralogía de Fallot (22%). Del cuestionario sobre
ERH se reporta una mediana de 7 meses en la demora del diagnóstico y se visitó entre 3 y 5 médicos.
Asimismo, el 30% consideró que le generó un gasto entre alto y muy alto. Se calculó que el presupuesto
para ERH constituye el 2,25% del presupuesto total para enfermedades de alto costo, asimismo, el
presupuesto para ERH fue diferente entre los años 2014 y 2019. Conclusión: La población con ERH en el
Perú no es numerosa; sin embargo, requiere una mayor atención para el acceso a los servicios de salud,
así como una mayor asignación presupuestal.
Palabras clave: Enfermedades raras; Costo de enfermedad; Economía; Economía de la salud; Perú
(fuente: DeCS BIREME).
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INTRODUCTION
Rare and orphan diseases (ROD) represent a challenge
today, as they only have 40 years of research(1).
Their denomination of "rare" assumes that they
constitute as low frequency diseases, an idea that
changes when evaluating them all together, since an
approximate of 7000 ROD is calculated for which the
World Health Organization (WHO) affirms that they
affect around the 7% of the world population under
the definition of a prevalence of less than 0.65% or
1%(1–5). The latest analysis, based on epidemiological
data from Orphanet, showed that the prevalence of
ROD is 3.5% -5.9% of the world population, which is
equivalent to 300 million affected people6.

It is important to highlight the medical journey
traveled by patients with a rare disease (and their
families) that, as Black et al. in his research, it is an
odyssey(8). The patient goes to a health center with
the first symptoms, but the doctor does not suspect
that it is a ROD, and thus, the patients will be referred
to many specialists without obtaining answers and
worsening their prognosis. For this reason, from the
first level of care, improvements such as empathy,
skills, and competencies for early diagnosis, good
management and follow-up of the patient, and
communication and research on the pathology, must
be emphasized. There are few specific treatments for
these pathologies. Still, specialized rehabilitation
in ROD is essential since these patients have a
lower quality of life than the general population,
and some will present significant disabilities.
Therefore, a rehabilitator who proposes personalized
improvement techniques is essential.
The big problem is that there are no reliable
epidemiological data on the prevalence and
incidence in national and global populations to
support public health interventions(9). This study aims
to determine the socio-economic characteristics of
ROD in Peru and demographic factors, estimate the

https://inicib.urp.edu.pe/rfmh/vol21/iss4/6
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METHODS
Design and study area
An observational and descriptive design study was
carried out, using data from Peru between the years
2014 and 2019.

Population and sample
The population corresponds to people affected
by rare and orphan diseases in Peru, obtained
from a database of administrative records of the
health sector, the Intangible Solidarity Health Fund
(FISSAL). In addition, a survey validated by Orphanet
was carried out on an intentional sample of 20
people or relatives of people affected by rare and
orphan diseases. For the economic part, the Ministry
of Economy and Finance was consulted. People
affected by diseases that do not appear in the list
of 399 rare diseases identified in the country or that
do not coincide with the respective ICD-10 were
excluded.

ORIGINAL PAPER

In Peru, in 2011, Law No. 29698 was approved,
declaring the treatment of people suffering from
ROD of national interest and preferential care. They
were grouped into categories: very high priority, high
priority, low priority, and very low priority. In total,
399 diseases were identified. It should be noted that
there is currently a new standard approved in 2019
by the Ministry of Health of Peru (MINSA) with RM
No. 1075-2019 / MINSA, for the List of Rare or Orphan
Diseases(7).

allocation of resources, and its economic impact in
the country.

Variables and instruments
The variables proposed were the sociodemographic
characteristics of the patients (age, gender, origin,
and comprehensive health insurance regime). As
well as the time elapsed between the first symptom
and the moment of diagnosis, how many doctors did
they consult between the first manifestation of the
disease and the diagnosis, if they gave you wrong
diagnoses before the final diagnosis, if looking for
the diagnosis required personal expense, if they
received complete information on their illness,
and if the patient or family received psychological
support and if their origin was from the city of Lima
or another (classified as "province"). Those inherent
to the economic aspect of these diseases were total
budget, budget execution, and unit cost.
The information was obtained from the database of
administrative records of the health sector, FISSAL;
A questionnaire validated by Orphanet was also
taken into account. For the economic data, a review
was made of the public budget of the Ministry of
Economy and Finance, the Integrated Financial
Administration System - Budget Monitoring
(SIAF), available at: https://apps5.mineco.gob.pe/
transparencia/Navegador/ default.aspx.
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Procedures

Ethical aspects

The information on the economic aspect was
obtained through the Modified Institutional Budget
of the FISSAL-MINSA per year between 2014 and
2019. The figures shown in this budget are used to
cover high-cost diseases such as Chronic Kidney
Failure on dialysis, cancers, and rare and orphan
diseases. For the first, approximately 60% is allocated,
approximately 40% to the problem of cancer and
only 2.25% to ROD (this is calculated with the data
that for the year 2017 the allocation of resources
for ROD was 5.8 million soles, that is, 2.25% of the
total). Therefore, the ROD budget for each year was
considered as 2.25% of the total budget for the same
year.

The study was approved by the Research Ethics
Committee of the Ricardo Palma University.

On the other hand, the data collection of the
Orphanet questionnaire was carried out through
contact with the ESPERANTRA organization, which
facilitated the meeting with patients to conduct
interviews with them or their relatives in different
hospital centers in Lima with different pathologies
anonymously.

Statistical analysis
A descriptive analysis of the variables studied was
carried out, using central tendency and dispersion
measures for the quantitative variables and
frequencies and percentages for the qualitative
ones. Inferential analysis was carried out to compare
the budget for ROD in 2015 against that of 2019; for
this, the non-parametric Mann Whitney U test was
used. SPSS version 25 and Microsoft Excel were used
to process the database.
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RESULTS
454 patients were registered with a total of 49 ROD
according to the database in Peru. Regarding age,
they were grouped: Newborns were 29 patients
(6%), younger and older infants, 86 (10% and 9%
respectively), preschoolers, 78 (17%), schoolchildren,
81 (18%), adolescents , 39 (8%), young adults, 80
(18%), mature adults, 36 (8%), older adults, 3 (1%)
and no age, 22 (5%). Most were male (243, 54%). The
origin of the majority was from the department of
Lima (266, 59%), the one that follows in frequency
is Junín with 20 patients (4%), 6% does not register
origin, and the rest is distributed among the other
Peruvian departments and the Callao province.
The regimen by which patients are cared for the
most part is subsidized (442.97%), SIS NRUS (6.1%),
semi-contributory (3.1%), independent SIS, and
independent insurance with 2 and 1 patients,
respectively. Among the most diagnosed diseases
are: Tetralogy of Fallot (102 patients, 22%), Systemic
lupus erythematosus (87, 19%), gastroschisis (39,
9%), hemophilia A (34, 7%), osteogenesis imperfecta
(30, 7%), the rest is divided among the other 44 listed
diseases (Graph 1). These diseases can be divided by
their cause (if they are genetic or not); thus, 67%
(33 diseases) are, but they only constitute 39% of all
patients (177).
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Source: FISSAL, own elaboration.

Graphic 1. Diagnoses of people affected with rare and orphan diseases in Peru, 2017-2019.
On the other hand, the sociodemographic data
obtained from the surveys carried out on an

https://inicib.urp.edu.pe/rfmh/vol21/iss4/6
DOI: https://doi.org/10.25176/RFMH.v21i4.3936

intentional sample of 20 people can be seen in Table
1.
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Table 1. Sociodemographic data of patients with rare and orphan diseases in Peru (ORPHANET survey,
intentional sample of 20 people), 2019Incorrect.
Doctors consulted

diagnoses

Expenditure

Information

Psychological support

Origin

3a5

Yes

Very High

Yes

No

Province

at birth

1

No

Little

No

Yes

Lima

at birth

1

No

Little

Yes

Yes

Province

2 years

3a5

No

Little

Yes

Yes

Province

2.5 years

3a5

Yes

Moderate

Yes

Yes

Province

3 years

3a5

Yes

High

Yes

No

Lima

9 months

3a5

No

Moderate

Yes

No

Province

3 years

3a5

No

No

Yes

No

Province

1 year

1a2

No

Little

Yes

No

Lima

1.5 years

1a2

Yes

Very High

Yes

No

Province

5 months

3a5

Yes

Moderate

Yes

No

Lima

1 month

3a5

No

High

Yes

No

Province

6 months

3a5

No

Very High

Yes

Yes

Province

2.5 years

3a5

No

High

Yes

Yes

Province

6 months

1a2

No

Moderate

Yes

Yes

Province

6 months

3a5

No

Moderate

Yes

Yes

Province

6.5 years

1a2

Yes

Little

Yes

No

Province

1 month

3a5

No

Little

Yes

Yes

Lima

1 year

3a5

No

No

No

No

Province

3 months

1a2

No

Moderate

No

Yes

Lima

Time

ORIGINAL PAPER

6 months

Time: elapsed between the first symptom and the moment of diagnosis. Doctors consulted: between the first
manifestation of the disease and the diagnosis. Misdiagnoses - If you received misdiagnoses before the final diagnosis.
Expense: level of expense caused by seeking the diagnosis. Information: if you received complete information about
your illness. Psychological support: if the patient or family received psychological support. Province: City outside the
department of Lima.
Source: ORPHANET survey, own elaboration.

As can be seen in the first column of this table, the
longest time elapsed between the appearance of
the first symptom and the moment of diagnosis
was 6.5 years, followed by 3 years and in 2 cases was
diagnosed at birth. The mean of these results is 1.33,
which would mean that on average, the diagnosis
would take 1 year and 3 months, but the standard
deviation is 1.57, which warns of outliers that make
the average unreliable. For this reason, the median is
used, which was 0.6, which indicates that half of the
patients after 7 months of the first symptom already
had their diagnosis. 65% went between 3 to 5 doctors
until they reached the definitive diagnosis and 35%
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from 1 to 2. Of the 20 patients surveyed, 6 of them
(30%) gave a wrong diagnosis before reaching the
final diagnosis. Regarding the disbursement made by
each relative with a patient with the rare and orphan
disease to reach the diagnosis only, it was: 10% did
not generate expenses. 30% little, 30% moderate,
and 30% high to very high. 85% of those surveyed
received complete information about their illness or
their family member at the time of diagnosis. Unlike
the information about the disease, psychological
support was given to only half of the patients and/or
relatives. Most of the people interviewed came from
the provinces of Peru (70%) and 30% from Lima.
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In Table 2, you can see the total budget (Total FISSAL
Budget) aimed at treating high-cost diseases and
ROD, the executed budget, and the estimated

budget allocated to ROD for each year, estimated
from 2.25% of the total budget for that year.

Table 2. Total budget in soles of FISSAL compared to the budget directed to rare and orphan diseases, Peru
2014-2019.
TotalFISSAL Budget

budgetexecution

Estimate (2.25% of the
total budget) of the budget allocated to ROD

2019

348 122 954

346.3 million

7.8 million

2018

418 523 371

398.2 million

9.4 million

2017

257 726 602

257.4 million

5.8 million

2016

192 943 209

192.8 million

4.3 million

2015

190 196 344

189.5 million

4.2 million

2014

152 196 791

151.7 million

3.4 million

ORIGINAL PAPER

Year

ROD: Rare and orphan diseases.
FISSAL: Intangible Solidarity Health Fund
SOURCE: FISSAL, own elaboration

The budgetary data of FISSAL attributed to ROD
(2.25% of the total) by departments in Peru for
the years 2015 and 2019 were taken to analyze
them comparatively. In the first instance, with
the Kolmogórov-Smirnov test, it was possible to
determine that the data do not have a normal
distribution. For this reason, the nonparametric
Mann-Whitney U test was used to face the budgets
for ROD for 2015 compared to 2019, resulting in
a p-value of 0.003; Therefore, the null hypothesis
is rejected, that is, the median budget directed to
ROD in the different provinces of Peru, is different
between the years 2015 and 2019.

some rare or orphan disease, when transferred to
Peru, between 1.5 to 2 million would be affected(11).
Hypothetically, so the road is still long to have an
accurate figure in the country.

DISCUSSION

54% were male. Similar to Colombia in a study on
mortality due to ROD, it was found that 51.4% were
men of all ages(12), although with this it cannot be
affirmed that the frequency of appearance is higher
in them, since another study also in Colombia(10),
found that 53.96% of patients with ROD were
women.

Sociodemographic data
The findings obtained show that 49 ROD of the 399
listed. In contrast to these figures, in the United
States, they estimate that between 25 and 30 million
patients have a ROD. In the European Union, it
reaches approximately 27 to 36 million(9). Few of the
Latin American countries report accurate data, one of
them is Colombia, which estimates in 2013 a total of
13,173 patients(10). On the other hand, if we consider
that 5 to 7% of the world's population suffers from
https://inicib.urp.edu.pe/rfmh/vol21/iss4/6
DOI: https://doi.org/10.25176/RFMH.v21i4.3936

Schoolchildren and young adults are the majority of
patients, with 18% each. Still, if evaluated together,
between newborns and all children, they add up
to 60%, so these are diseases that occur more
frequently in pediatric age. This agrees in part with
the authors Carbajal and Navarrete(4), who affirm that
approximately 50% appears in pediatric age. Still, the
highest prevalence is seen in adults due to excessive
infant mortality due to these diseases.

The origin of more than half of the patients is from
the capital, Lima. The other departments have a very
low percentage, but this may be due to their underregistration because it is difficult to diagnose and
identify them even more outside the capital.
Pág. 715
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71% of patients are cared for in health facilities
with a subsidized regime, which is the mechanism
by which the population without the ability to pay
access health services; in other words, it is the most
impoverished population in the country.

ORIGINAL PAPER

In the literature, it is found that 72% of ROD are
genetic and 70% of them begin in childhood,6 the
finding of the present study is close to this figure since
67% or 33 diseases are genetic such as hemophilia A
and osteogenesis imperfecta , but if the distribution
among the patients is seen, they only constitute 39%
(177 patients), the other 277 suffer from congenital,
acquired, multifactorial diseases or still of unknown
etiology.
A study in China(13) chooses to study 7 rare diseases
of their country, of which only Gaucher disease
matches our list. Carbajal and Navarrete(4) list "the
rarest and most curious diseases in the world,"
and only one coincides (Moebius syndrome). In
the study of mortality due to orphan diseases in
Colombia(12) cited above, gastroschisis is the only
one that matches our list. It was a frequent cause of
death in men and women; in still lack this data in our
country. Of the most frequent pathologies according
to the research of María Pareja(10), two coincide
with the findings of this study: Hemophilia A and
Von Willebrand's disease, which occupy the fourth
and fourteenth place in our results. In addition, his
research includes the percentage of people with
ROD with disabilities, which was 10.74% of the total,
data that is not required in Peru either.
Several RODs can be diagnosed prenatally, which
is important because it facilitates delivery and
newborn care, ensures their well-being as much as
possible, and suggests a better future prognosis(14).
Based on what was found in this study, of the 49
diseases, 13 can be diagnosed or at least suspected
in utero (tetralogy of Fallot, gastroschisis, among
others), by means of routine prenatal ultrasounds
that refer to more specific tests, another 12 can
be diagnosed prenatally if family history is known
(hemophilia, primary agammaglobulinemia, cystic
fibrosis, phenylketonuria, for example).
Neonatal screening is another way to detect ROD, in
2012 the law established interest for the screening
of 6 pathologies in Peru(15), of which phenylketonuria
and cystic fibrosis are ROD on the list. Just for
comparison, the United States has 32 diseases for
newborn screening(16), including the 2 diseases
mentioned.
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Based on the questionnaire, data were obtained that
may or may not reflect the reality of rare and orphan
diseases in the country, but it gives us a general idea.
First, it is obtained that the delay in diagnosis was
up to 7 months for half of the patients, a fact that
does not agree with the information collected in the
bibliography; for the other half, it took from 1 to 6.5
years for the final diagnosis. Regarding the number
of doctors who were seen, a marked majority is seen
in the range of 3 to 5, without obtaining results
greater than this. Regarding the impoverishment
of the families, 12 people affirmed that reaching
the diagnosis represented a moderate, high and
very high expense, while for the other 8 it was
little or none. At this point, it should be taken into
account that the question only refers to the direct
expenditure of the families to reach the diagnosis,
without considering other expenses such as followup of the pathology, the price of medicines in some
cases for life, rehabilitation, other products health
and necessary care in addition to the high level of
dependency that most of these patients have. In
addition, the health insurance scheme they have was
not included.
It is very important to provide complete information
to the patient and/or relatives about the disease so
that they take care of themselves and know what to
expect from the disease in terms of complications
and prognosis to make the quality of life the best
possible, in addition to identifying the nature of
the pathology so that, if it is the case of having
genetic inheritance, that data can be known within
the family, 85% of the people surveyed did receive
this information; it was different in the case of
psychological support since only half received it.
Psychological support for the patient and their
families is important, as in other cases as well, due
to the high emotional impact, doubts, and fears that
these diagnoses carry.
70% of the people surveyed came from the province,
and in their entirety, they agreed that their stay in
Lima was for some reason related to their illness or
that of their relative, such as diagnosis, treatment
or better conditions in terms of follow-up of their
illness.

Budget
Regarding the budget, there is mostly an increasing
trend as the years go by, and the highest amount
assigned to ROD was that of 2018 with 9.4 million
if we compare this figure with the 53.4 million soles
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that are required to pay for at least the first 8 diseases
on the list, reflecting that it only covers 17.6%.
Therefore, the insufficient budget allocated to ROD
is evident.

Cost

Authorship contributions: The authors developed
the original idea of the project, the planning of the
work, the execution of the project, the review, and
analysis of the results, and the elaboration of the
article.

The study has certain limitations since, being based
on secondary sources, there could be errors regarding
the diagnoses or underreporting. The comparison
with other countries is minimal since the prevalence
of the diseases can vary in different populations, thus
being rare in some and more frequent in others, and
there are few data worldwide. Its most significant
strength is that it gives a broader vision of the reality
that was had in Peru regarding ROD, which is a great
step for public health.

CONCLUSION
In conclusion, the population with ROD in Peru is not
large; however, it requires greater attention to access
to health service and a greater budget allocation.

Funding sources: Self-financed.
Conflict of interest: The authors declare that they
have no conflict of interest.
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Similar cases that denote the high cost of ROD can
be found in the literature, for example, in Germany,
in a study it is calculated that the cost of Annual
treatment per patient with ROD is between € 27,811
and € 1,647,627 (S /. 104,013 and S /. 6,162,124), they
also analyze the impact on the annual budget of ROD
and ultra-rare in Europe, which it was on average €
677,975,264 (S /. 2,535,627,487) but of this amount,
pharmaceutical spending only constituted 2.7%
(0.7–7.8)(17). Another study carried out a literature
review (mostly European) that facilitated the prices of
medicines for ROD, from which they concluded that
the annual cost ranged from € 1,474 to € 912,000 (S /.

1,772 to 3,410,880 ) per patient, that is, an average of
€ 96,518 (S /. 360,977)(18).
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